The CEO of CureVac, Franz-Herner Haas, states in the press release that the company wants to make a difference with a safe and effective vaccine. “This goal has not changed, but the requirements to efficiently deal with the virus and its emerging variants have changed.” The decision to focus on the second-generation mRNA candidate vaccine reflects “anticipated changes in public health needs that our second-generation may be able to address,” it said.
The COVID collaboration between CureVac and GSK builds on an existing mRNA technology partnership that both companies entered into in July 2020. The joint development focuses on improved second-generation mRNA vaccines, which have the potential to target different COVID-19 variants, target different diseases in a combination dose and provide better forms of inoculations.
–
